Form D · Biotechnology

Entheon Biomedical Corp. / Federal

Coquitlam, A1 · CIK 0001843655

Offering snapshot reported Feb 3, 2021 · SEC filing

Reported sold: $31.4K
Investors reported: 1
Minimum accepted: $0
First sale: Jan 11, 2021

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Feb 3, 2021	Initial	$31,390	No comparison	1	SEC filing

Offering details

Securities: Equity, Option to acquire, Security to be acquired, Other
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-388338

The additional $1,675,798.00 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada average rate of exchange reported on 1/11/2021, which was Cdn$1.2788=US$1.00.

Each unit is comprised of 1 common share and 1/2 of one non-transferable common share purchase warrant. Each whole warrant is exercisable for 1 common share at an exercise price of Cdn$1.00 per share for a period of 24 months, subject to acceleration.

Source: Form D, filed Feb 3, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Ruth Chun	Director
Christopher Gondi	Director
Andrew Hegle	Director, Executive
Timothy Ko	Director, Executive
Kelly Pladson	Executive
Brandon Schwabe	Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:

211 3030 Lincoln Avenue
Coquitlam, A1, V3B 6B4